May 8 (Reuters) - The U.S. Food and Drug Administration has approved Verastem's VSTM.O combination therapy for patients with a type of ovarian cancer who have received prior treatment, the regulator said on Thursday.
(Reporting by Sriparna Roy in Bengaluru; Editing by Leroy Leo)
((Sriparna.Roy@thomsonreuters.com;))